The concept of multimorbidity has attracted growing interest over recent years, and more
latterly with the publication of specific guidelines on multimorbidity by the National Institute …

In patients with Parkinson's disease, heterogeneous cholinergic system changes can occur
in different brain regions. These changes correlate with a range of clinical features, both …

Dopamine loss in the substantia nigra causes several of the motor signs seen in Parkinson's
disease, but there is now increasing evidence highlighting the importance of cholinergic loss …

Objective: Nonmotor symptoms (NMS) are common in patients with established Parkinson
disease (PD) but their frequency in early PD has not been extensively studied. Our aim was …

Objective: To describe the frequency of mild cognitive impairment (MCI) in Parkinson
disease (PD) in a cohort of newly diagnosed incident PD cases and the associations with a …

Nonmotor symptoms (NMS) are common in patients with established Parkinson's disease
(PD) and have a major impact upon quality of life. We investigated the significance of NMS …

Background The immune system is a promising therapeutic target for disease modification in
Parkinson's disease (PD), but appropriate immune‐related biomarkers must be identified to …

Mild cognitive impairment in Parkinson's disease is associated with progression to dementia
(Parkinson's disease dementia) in a majority of patients. Determining structural imaging …

Gait disturbance is an early feature in Parkinson's disease. Its pathophysiology is poorly
understood; however, cholinergic dysfunction may be a non-dopaminergic contributor to …

Introduction Parkinson's disease dementia (PDD) is associated with poorer quality of life
(QoL). Prior to the onset of PDD, many patients experience progressive cognitive …